Information  X 
Enter a valid email address

Mereo BioPharma Grp (MPH)

  Print      Mail a friend

Friday 13 September, 2019

Mereo BioPharma Grp

Directors' details update

RNS Number : 3369M
Mereo BioPharma Group plc
13 September 2019
 

Mereo BioPharma Group plc

 

 ("Mereo" or the "Company" or the "Group")

 

Directors' details - Update

 

London and Redwood City, Calif., September 13, 2019 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today announces the additional details on Directors' disclosures in the Appendix below.

 

Further Enquiries:

 

Mereo

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer


Richard Jones, Chief Financial Officer




Cantor Fitzgerald Europe (Nominated Adviser and Broker to Mereo)

 +44 (0)20 7894 7000

Phil Davies


Will Goode




FTI Consulting (Public Relations Adviser to Mereo)

+44 (0)20 3727 1000

Simon Conway


Brett Pollard


Ciara Martin




Burns McClellan (US Public Relations Adviser to Mereo)

+01 (0) 212 213 0006

Lisa Burns


Steve Klass


 

Appendix

 

Directors' disclosures

 

The Company makes the following disclosures pursuant to Rule 17 and Schedule Two (g) of the AIM Rules for Companies

 

Anders Ekblom, Non-Executive Director of Mereo, was at the time of the publication of the  Company's admission document dated 3 June 2016 ("Admission Document"), a director of NXT Science AB, Sallheten Invest AB and TFS Trial Form Support International AB.

 

Deepa Pakianathan, Non-Executive Director of Mereo, was at the time of her appointment as a director of the Company on 23 April 2019, a director of Serplus Technology LLC.  This disclosure corrects the name Serplus Bio, previously disclosed by the Company on 23 April 2019.

 

Kunal Kashyap, Non-Executive Director of Mereo, had in the five years prior to publication of the Admission Document, been a director of Bharti Life Ventures Pvt Limited and Bharti General Ventures Pvt Limited.

 

Michael Wyzga, Non-Executive Director of Mereo, was at the time of his appointment as a director of Mereo on 23 April 2019, a Director of International Institute of New England Inc. and, in addition, Mr Wyzga was a director of Altus Pharmaceuticals, Inc. in 2009 when it filed for Chapter 7 bankruptcy. The assets of Altus Pharmaceuticals, Inc. were later sold. 

 

Paul Blackburn, Non-Executive Director of Mereo, was, at the time of publication of the Admission Document, a director of Manawatu Management Company (Beaconsfield) Limited.

 

Richard Jones, Chief Financial Officer of the Company, had in the five years prior to announcement of his appointment as a director of Mereo on 7 November 2016, been a director of The Cambridge Crystallographic Data Centre.

 

The Admission Document  or, where relevant, the announcement of director appointment, omitted the directorship details above.

 

There are no further disclosures to be made pursuant to Rule 17 of the AIM Rules for Companies.

 

About Mereo BioPharma

 

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy is to selectively acquire product candidates for rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo's existing portfolio consists of six clinical stage product candidates. 

 

·      Setrusumab for osteogenesis imperfecta (OI). In October 2018, the Company announced completion of enrollment of 112 adult patients in a Phase 2b dose ranging study with initial positive 6-month open label data announced in May 2019 and top-line 12-month blinded dose ranging data expected in Q4 2019. A pediatric Phase 3 study design has also been approved by the EMA. Setrusumab has orphan designation in the U.S. and the EU and has been accepted into the PRIME and Adaptive Pathways in EU;

 

·      Alvelestat for alpha-1 antitrypsin deficiency (AATD). The Company has initiated a Phase 2 proof-of-concept clinical trial in patients with severe AATD in the United States and the EU and expects to report top-line data from this trial around the end of 2019;

 

·      Acumapimod for severe exacerbations of COPD. The Company announced positive Phase 2 data in May 2018 and recently announced the outline of the pivotal Phase 3 study including the primary and key secondary endpoints following the successful end of Phase 2 Type B meeting with the FDA;

 

·      Leflutrozole for hypogonadotropic hypogonadism (HH). The Company announced positive top-line Phase 2b data in March 2018 and positive results from the Phase 2b safety extension study in December 2018;

 

·      Navicixizumab has completed a Phase 1a single-agent clinical trial in patients with advanced solid tumors and is currently in a Phase 1b trial in combination with a standard paclitaxel regimen in patients with platinum-resistant ovarian cancer. This study recently completed enrollment and the Company has held a successful Type B meeting with the FDA outlining a path for Accelerated Approval; and

 

·      Etigilimab has completed a single-agent Phase 1a trial in patients with advanced or metastatic solid tumors and the Phase 1b combination study with nivolumab has fully enrolled and is currently in the safety monitoring phase.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RDNZXLFFKKFFBBL

a d v e r t i s e m e n t